A next-generation plant
A « next-generation » facility
In line with its international growth and development, LFB is developing its production capacity with a next-generation facility, currently under construction. This new facility should triple LFB’s overall capacity for producing plasma-derived medicinal products.
Manufacturing in France for the whole world
Near Arras (Pas-de-Calais), this 11,000-square-meter plant on the ground, will be producing 10% immunoglobulins, fibrinogen and albumin – all being medicinal products that are increasingly in demand in France and worldwide.
The new facility is designed principally to optimise production costs and respond to the highest global standards; it will therefore enable LFB to supply the whole world with products made in France.
The Arras plant: under qualification
Final cleaning and sterilisation of the production facilities have started, and the commissioning of equipment in the production units is now underway. The first performance qualifications have started on the filling lines.
The control laboratories and waste valorisation unit are fully built.